logo-loader
viewLexagene Holdings Inc.

LexaGene Holdings reports favorable beta test results on its infectious disease diagnostic in animals

LexaGene Holdings Inc (OTCQB: LXXGF)(CVE: LXG) CEO and Founder Dr Jack Regan tells Proactive Investors the biotech company has reported favorable beta test results from its infectious disease diagnostic analyzer in animals at the Massachusetts Veterinary Referral Hospital.

Dr. Regan says the company's test returns results are produced in about one hour versus three or more days.

Quick facts: Lexagene Holdings Inc.

Price: 0.94 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $80.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene working hard to manufacture genetic analyzer that...

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) CEO Jack Regan tells Proactive the biotechnology company is working as hard as it can to get its diagnostic instrument that can be configured to detect threats like Coronavirus, into the hands of people who need it. Regan also explained the...

3 weeks, 4 days ago

2 min read